Clinical Trial Update: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing cenicriviroc for nonalcoholic steatohepatitis with liver fibrosis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cenicriviroc (cenicriviroc)

Snippet

Sponsor: Tobira Therapeutics, Inc. | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-10